Martee L Hensley

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
  2. ncbi Non-mammary metastases to the breast and axilla: a study of 85 cases
    Deborah F Delair
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:343-9. 2013
  3. ncbi Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer
    M M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 129:38-41. 2013
  4. ncbi Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis
    Mario M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 125:409-13. 2012
  5. ncbi Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach
    Mario M Leitao
    Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 125:394-9. 2012
  6. ncbi Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
    Robert A Soslow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 25:625-36. 2012
  7. ncbi Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma
    Mario M Leitao
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 124:558-62. 2012
  8. ncbi CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study
    Ginger J Gardner
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 124:216-20. 2012
  9. ncbi Reproductive issues in the gynecologic cancer patient
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 21:598-606; discussion 606-9. 2007
  10. ncbi Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 108:191-4. 2008

Detail Information

Publications154 found, 100 shown here

  1. ncbi CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
    ..A secondary objective was to assess the relationship of CA125 level to PFS...
  2. ncbi Non-mammary metastases to the breast and axilla: a study of 85 cases
    Deborah F Delair
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:343-9. 2013
    ..This finding emphasizes the need to accurately identify these tumors as metastases in order to avoid unnecessary procedures and treatments in these patients...
  3. ncbi Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer
    M M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 129:38-41. 2013
    ..To determine whether the frequency of cases diagnosed with stage IIIC endometrial cancer is affected by the incorporation of a modified surgical lymph node assessment...
  4. ncbi Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis
    Mario M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 125:409-13. 2012
    ..To determine whether cytoreduction is associated with improved outcome in patients newly diagnosed with metastatic uterine leiomyosarcoma (LMS)...
  5. ncbi Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach
    Mario M Leitao
    Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 125:394-9. 2012
    ..To assess the introduction of computer-based surgery (ie, robotic surgery [RBT]) in the treatment of patients with newly diagnosed uterine cancer...
  6. ncbi Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
    Robert A Soslow
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 25:625-36. 2012
    ..60 (95% CI, 0.32-0.84) and a negative predictive value of 1.0 (95% CI, 0.63-1.0)). These preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas...
  7. ncbi Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma
    Mario M Leitao
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 124:558-62. 2012
    ..We assessed the IHC expression of ER and PR and their prognostic significance in uterine leiomyosarcoma (LMS)...
  8. ncbi CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study
    Ginger J Gardner
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 124:216-20. 2012
    ..The purpose of this study is to identify the rate of CA125 regression during intraperitoneal (IP) versus intravenous (IV) chemotherapy for ovarian cancer...
  9. ncbi Reproductive issues in the gynecologic cancer patient
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 21:598-606; discussion 606-9. 2007
    ..Education and support are clearly an essential component of cancer survivorship. Furthermore, more attention and investigation is still needed about the reproductive issues of gynecologic cancer survivors in the future...
  10. ncbi Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 108:191-4. 2008
    ..To date, only one prediction model has been reported for patients with epithelial ovarian carcinoma (EOC). The objective of this study was to develop a more accurate survival nomogram for patients with bulky stage IIIC EOC...
  11. ncbi Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual dis
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA or
    J Clin Oncol 25:4946-51. 2007
    ..To compare surgeons' operative assessments of residual disease (RD) to those identified on postoperative computed tomography (CT) scans in patients with advanced ovarian carcinoma reported to have undergone optimal primary cytoreduction...
  12. ncbi Initial experience with Dargent's operation: the radical vaginal trachelectomy
    Y Sonoda
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 108:214-9. 2008
    ..To report on our initial experience with radical vaginal trachelectomy for patients with early-stage cervical cancer...
  13. ncbi The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology
    D S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Int J Gynecol Cancer 18:269-73. 2008
    ..These data are more applicable to current surgical practice than the previously described one-third myometrial invasion cutoff results...
  14. ncbi Current and future surgical approaches in the management of endometrial carcinoma
    Mario M Leitao
    Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, 1275 York Avenue, NY 10065, USA
    Future Oncol 4:389-401. 2008
    ..Surgical cytoreduction of metastatic disease is also associated with improved outcomes...
  15. ncbi Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 109:329-34. 2008
    ..Fixed-dose rate gemcitabine plus docetaxel is active as second-line therapy for metastatic uterine leiomyosarcoma. We sought to determine the activity of this regimen as first-line treatment...
  16. ncbi Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer
    Kaled M Alektiar
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 112:142-5. 2009
    ..To report a single institution experience in surgical stage I-II serous endometrial cancer using combined carboplatin/paclitaxel and intravaginal radiation (IVRT)...
  17. ncbi A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:335-41. 2007
    ..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure...
  18. ncbi Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches
    Richard R Barakat
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 105:150-6. 2007
    ..The purpose of this study was to analyze the results of these changes...
  19. ncbi Psychiatric illness presenting with a sexual complaint and management by psychotropic medications: a case report
    Michael Krychman
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Sex Med 5:223-6. 2008
    ..The rare disorder of reverse delusional misidentification syndrome may be encountered in schizophrenic patients and may be best managed by the combined team effort of a sexual medicine specialist and psychiatrist...
  20. ncbi Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells
    Jakob Dupont
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Joan and Sanford Weill Medical College of Cornell University and Immunology Program, Sloan Kettering Institute, New York, New York 10021, USA
    Cancer Res 65:5417-27. 2005
    ....
  21. ncbi Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancer
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 101:224-7. 2006
    ..The purpose of this study was to report the outcomes of a series of patients who underwent splenectomy for persistent or recurrent ovarian cancer via laparoscopy or hand-assisted laparoscopy...
  22. ncbi Screening and the prevention of gynecologic cancer: endometrial cancer
    Yukio Sonoda
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Best Pract Res Clin Obstet Gynaecol 20:363-77. 2006
    ..Screening for these cancers is not effective and often leads to additional unnecessary tests; thus, it is not currently recommended in the general population...
  23. ncbi Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 102:270-7. 2006
    ....
  24. ncbi Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma
    Dennis S Chi
    Gynecology Service, Department of Surgery Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1933-9. 2006
    ....
  25. ncbi Brain cancer and sexual health: a case report
    Michael L Krychman
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Palliat Support Care 2:315-8. 2004
    ..However, the sexual concerns of these patients are often overlooked. Brain cancer patients are no exception to this oversight...
  26. ncbi What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    D S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:559-64. 2006
    ..The objective of this study was to analyze survival rates at very specific residual disease diameters to determine the optimal goal of primary cytoreduction for bulky stage IIIC EOC...
  27. ncbi The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:714-8. 2006
    ..To describe the incidence of symptomatic postoperative lower-extremity lymphedema in women treated for uterine corpus cancer, and to evaluate its relationship to regional lymph node removal and postoperative therapy...
  28. ncbi Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:729-31. 2006
    ..To describe the role of temporary retrograde ureteral catheterization at the time of fertility-sparing radical vaginal or abdominal trachelectomy in women with early-stage cervical cancer...
  29. ncbi A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma
    Dennis S Chi
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 112:6-10. 2009
    ....
  30. ncbi Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 112:563-7. 2009
    ..We sought to determine whether adjuvant gemcitabine-docetaxel would yield a 2-year progression-free survival of at least 50% in this leiomyosarcoma population...
  31. ncbi Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma
    Mario M Leitao
    Department of Surgery, Division of Gynecology, Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065, USA
    Gynecol Oncol 113:105-8. 2009
    ..To compare the accuracy of D&C vs office endometrial biopsy in predicting final post-hysterectomy FIGO grade in patients diagnosed with a preoperative FIGO grade 1 endometrial adenocarcinoma...
  32. ncbi The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:38-42. 2010
    ..To assess the morbidity and mortality associated with extensive upper abdominal surgery (EUAS) performed during primary cytoreduction for advanced ovarian carcinoma...
  33. ncbi Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers
    Mario M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:208-11. 2010
    ..The primary objective of the current study was to determine whether the use of HA-CMC is associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for uterine or cervical malignancies...
  34. ncbi A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 119:358-65. 2010
    ..To prospectively assess and describe the emotional, sexual, and QOL concerns of women with early-stage cervical cancer undergoing radical surgery...
  35. ncbi Fertility considerations in the management of gynecologic malignancies
    Nicole Noyes
    Division of Reproductive Endocrinology, New York University School of Medicine, New York, NY 10016, USA
    Gynecol Oncol 120:326-33. 2011
    ..Fertility preservation (FP) has become an integral component in the selection and execution of gynecological cancer management. In this report we address gynecologic malignancies as they relate to future fertility potential...
  36. ncbi A cross-sectional cohort study of infertile women awaiting oocyte donation: the emotional, sexual, and quality-of-life impact
    Jeanne Carter
    Department of Psychiatry, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Fertil Steril 95:711-6.e1. 2011
    ..To examine the emotional, sexual, physical, and quality-of-life (QOL) impact on infertile women awaiting oocyte donation...
  37. ncbi Fertility-sparing surgery in early-stage cervical cancer: indications and applications
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York
    J Natl Compr Canc Netw 8:1435-8. 2010
    ..Investigation into alternative fertility-sparing adjuvant therapy in patients with node-positive disease is needed...
  38. ncbi Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship: the physician checklist
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, and Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 21:106-16. 2011
    ....
  39. ncbi The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered?
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Gynecol Cancer 21:511-6. 2011
    ..We sought to describe the overall survival (OS) of women with stage I endometrial cancer and examine how the estimated stage-specific OS is altered in the 2009 system...
  40. ncbi Surgical management of recurrent ovarian cancer
    Mario M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Semin Oncol 36:106-11. 2009
    ..Surgery also plays a role in the palliation of certain patients. Continued investigations, especially randomized trials, are needed to further define the optimal treatment modalities for these patients...
  41. ncbi Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Oncol 22:356-61. 2010
    ..The activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatric sarcomas is discussed...
  42. ncbi A cross-sectional study of the psychosexual impact of cancer-related infertility in women: third-party reproductive assistance
    Jeanne Carter
    Department of Psychiatry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Cancer Surviv 4:236-46. 2010
    ....
  43. ncbi Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 114:26-31. 2009
    ..To determine the impact on progression-free survival (PFS) and overall survival (OS) of a programmatic change in surgical approach to advanced epithelial ovarian cancer...
  44. ncbi The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes
    Nadeem R Abu-Rustum
    Memorial Sloan Kettering Cancer Centerm, 1275 York Ave, NY, NY 10065, USA
    Gynecol Oncol 115:236-8. 2009
    ..To describe the incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes...
  45. ncbi A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer
    Dennis S Chi
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncologist 14:835-9. 2009
    ..To obtain prospective outcomes data on patients (pts) undergoing palliative operative or endoscopic procedures for malignant bowel obstruction due to recurrent ovarian cancer...
  46. ncbi Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers
    Mario M Leitao
    Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 115:204-8. 2009
    ..To determine whether HA-CMC was associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for ovarian, fallopian tube, or primary peritoneal malignancies...
  47. ncbi Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 116:151-2. 2010
    ..Radical trachelectomy may broaden the treatment options for pregnant women with stage IB1 cervical cancer who have a strong desire to avoid definitive pregnancy termination and commence treatment without delay...
  48. ncbi A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care
    N R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:399-403. 2010
    ..Our objective was to develop a clinically useful nomogram in the hope of providing a more individualized and accurate estimation of overall survival (OS) following primary therapy...
  49. ncbi Endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology
    Mario M Leitao
    Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Obstet Gynecol 202:278.e1-6. 2010
    ....
  50. ncbi A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 117:317-23. 2010
    ..This study aimed to determine the feasibility and efficacy of using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a symptom scale for lymphedema of the lower extremity (LLE)...
  51. ncbi An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 124:10-4. 2012
    ..We analyzed the outcomes of patients treated with PDS at our institution during the same time period in which the EORTC-NCIC trial was conducted, using identical inclusion criteria...
  52. ncbi Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy
    R R Barakat
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3459-63. 2000
    ..To determine the frequency of developing abnormal pathologic changes in the endometria of tamoxifen-treated women. To characterize the type of pathologic changes involved...
  53. ncbi Optimal therapy and management of endometrial cancer
    Yukio Sonoda
    Department of Surgery, Memorial Sloan Kettering Cancer Center, Gynecology Service Academic Office, New York, NY 10021, USA
    Expert Rev Anticancer Ther 3:37-47. 2003
    ..Controversy in management exists as to the approach and extent of primary surgery as well as the indications for adjuvant therapy. Management of this disease is reviewed...
  54. ncbi Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up
    Richard R Barakat
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:694-8. 2002
    ..To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy...
  55. ncbi Cervical neoplasia and the HIV-infected patient
    Elizabeth Stier
    General Gynecology Section, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hematol Oncol Clin North Am 17:873-87. 2003
    ..Hopefully, as patients live longer and healthier on HAART, they will be more compliant with cervical cancer screening, and cervical cancer will become an increasingly rare disease...
  56. ncbi Laparoscopy 2003: oncologic perspective
    Nadeem R Abu-Rustum
    Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Clin Obstet Gynecol 46:61-9. 2003
  57. ncbi Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NewYork, NY 10021, USA
    Gynecol Oncol 91:402-9. 2003
    ..The aim of this study was to describe the feasibility and outcome of total laparoscopic radical hysterectomy with pelvic lymphadenectomy for stage I cervical cancer using the argon-beam coagulator...
  58. ncbi Management of early ovarian cancer
    Yukio Sonoda
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 18:343-56; discussion 358, 361-2. 2004
    ..Ideally, these patients should have access to a gynecologic oncologist prior to their initial surgical procedure...
  59. ncbi Recurrent cervical cancer
    Mario M Leitao
    Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, c o Gynecology Service Academic Office, 1275 York Avenue, Room MRI 1027, New York, NY 10021, USA
    Curr Treat Options Oncol 3:105-11. 2002
    ..Patients whose recurrences extend close to the pelvic sidewalls should be referred to centers where HDR-IORT is available...
  60. ncbi Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique
    Nadeem R Abu-Rustum
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 89:504-13. 2003
    ....
  61. ncbi A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?
    Yukio Sonoda
    Department of Surgery, Gynecology Service Acadenic Office, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 95:534-8. 2004
    ..To determine the percentage of patients with early-stage cervical cancer who may be eligible for fertility preservation with laparoscopic radical vaginal trachelectomy (LRVT)...
  62. ncbi Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus
    Mario M Leitao
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 91:209-12. 2003
    ..The purpose of this study was to determine the incidence of lymph node and ovarian metastases in newly diagnosed uterine leiomyosarcoma (LMS), and to describe possible predictive factors...
  63. ncbi The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 94:307-11. 2004
    ..To analyze the findings and impact on the management of video-assisted thoracoscopic surgery (VATS) before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions...
  64. ncbi Gynecologic cancer treatment and the impact of cancer-related infertility
    Jeanne Carter
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 97:90-5. 2005
    ..The objective of this study was to empirically assess the emotional and sexual impact of cancer-related infertility in women with a history of gynecologic cancer...
  65. ncbi Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 94:650-4. 2004
    ....
  66. ncbi The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Obstet Gynecol 192:1614-9. 2005
    ..To compare the safety and efficacy of laparoscopic staging of ovarian or fallopian tube cancers to staging via laparotomy for epithelial ovarian carcinoma...
  67. ncbi Temozolomide in uterine leiomyosarcomas
    Sibyl Anderson
    Developmental Chemotherapy, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, Gynecology Breast Services Academic Office, 1275 York Avenue, MRI 1027, New York, NY 10021, USA
    Gynecol Oncol 98:99-103. 2005
    ..We include a literature review of temozolomide activity in leiomyosarcoma patients...
  68. ncbi Subcutaneous tumor implantation after laparoscopic procedures in women with malignant disease
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Obstet Gynecol 103:480-7. 2004
    ..To describe the incidence of clinically detected laparoscopy-related subcutaneous tumor implantation in women with malignant disease who were treated by a gynecologic oncology service...
  69. ncbi Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disea
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, MRI 1026, 1275 York Ave, New York, NY 10021, USA
    Int J Gynecol Cancer 20:353-7. 2010
    ..This is a follow-up analysis of survival and prognostic factors for patients who had concordant and discordant postoperative CT scan findings...
  70. ncbi The effects of CO2 pneumoperitoneum on the survival of women with persistent metastatic ovarian cancer
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 90:431-4. 2003
    ....
  71. ncbi Radical trachelectomy via a trans-sacral approach: a case report
    Yukio Sonoda
    Department of Gynecologic Oncology, Centre Oscar Lambret, Lille, France
    Gynecol Oncol 90:466-70. 2003
    ..Endometrial cancer may arise in patients previously treated for rectal cancer. Surgical management can be challenging, and the gynecologic oncologist may need to employ alternative surgical approaches...
  72. ncbi Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
    ..The median time to progression was 5.6 months (range, 4 to 10 months). CONCLUSION: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS...
  73. ncbi A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma
    Vicky Makker
    Memorial Sloan Kettering Cancer Center Department of Medicine, Gynecologic Medical Oncology Service, New York, NY, USA
    Gynecol Oncol 111:249-54. 2008
    ..To determine the progression-free survival (PFS) and overall survival (OS) in a cohort of patients who received either platinum-based chemotherapy with or without radiation therapy (pelvic or WAI), or RT alone...
  74. ncbi The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment
    Roisin O'Cearbhaill
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:326-31. 2010
    ....
  75. ncbi Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors
    Roisin O'Cearbhaill
    Department of Medicine, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 116:424-9. 2010
    ..Aromatase inhibitors are sometimes used in the treatment of selected patients with uterine leiomyosarcoma (LMS), but there are few data assessing the efficacy of aromatase inhibitors in this setting...
  76. ncbi Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study
    Mika A Sovak
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:451-7. 2006
    ..CONCLUSION: TC is a well tolerated, active regimen in the treatment of resected, high-risk stage III and IV endometrial cancer that warrants further investigation...
  77. ncbi Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
  78. ncbi Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk
    Mario M Leitao
    Division of Gynecology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Obstet Gynecol 203:349.e1-6. 2010
    ..The objective of the study was to identify additional factors that may improve the ability to predict underlying carcinoma risk in patients with complex atypical hyperplasia (CAH) of the uterus...
  79. ncbi Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers
    Kara C Long
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 120:33-7. 2011
    ..To evaluate the incidence and risk factors for ventral hernia development following primary laparotomy for ovarian, fallopian tube, and peritoneal cancers...
  80. ncbi Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life
    Martee L Hensley
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
    Gynecol Oncol 89:440-6. 2003
    ..We sought to determine whether anxiety, depression, perception of ovarian cancer risk, and false-positive test frequency differed between high-risk premenopausal and postmenopausal women initiating ovarian cancer screening...
  81. ncbi Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  82. ncbi A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    Jason Konner
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 110:140-5. 2008
    ..Determine the safety and efficacy of cetuximab plus paclitaxel and carboplatin as initial treatment of stage III/IV ovarian cancer...
  83. ncbi Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
    Jason A Konner
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5288-95. 2010
    ..This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD)...
  84. ncbi What is the incidence of isolated paraaortic nodal recurrence in grade 1 endometrial carcinoma?
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 111:46-8. 2008
    ..To describe the incidence of isolated paraaortic nodal recurrences in patients with a final diagnosis of grade 1 endometrial carcinoma initially treated with surgery...
  85. ncbi Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Clin Oncol 26:247-51. 2003
    ..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine...
  86. ncbi Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 115:460-5. 2009
    ..We also aimed to characterize the toxicity of sunitinib and to estimate time-to-progression...
  87. ncbi A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 14:6310-6. 2008
    ..To determine the maximally tolerated dose (MTD) of biweekly pemetrexed with gemcitabine plus B(12) and folate supplementation in patients with advanced solid tumors and ovarian cancer...
  88. ncbi Cognitive functions in long-term survivors of ovarian cancer
    Denise D Correa
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 119:366-9. 2010
    ..This cross-sectional study assessed neuropsychological functions in long-term survivors of ovarian cancer who were either in complete remission or with evidence of recurrent disease...
  89. ncbi Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer
    Monica Prasad
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:223-8. 2004
    ..Topotecan was more costly to deliver. Although a larger percentage of patients received clinical benefit with topotecan use, this likely reflects physician selection for use of topotecan earlier in the course of disease...
  90. ncbi Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  91. ncbi Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, Department of Medical Oncology, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 109:323-8. 2008
    ..There is no standard second-line therapy. We determined activity of fixed-dose rate gemcitabine plus docetaxel as second-line treatment for metastatic uterine leiomyosarcoma...
  92. ncbi Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer
    Paul J Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4170-7. 2007
    ....
  93. ncbi A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
    ..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...
  94. ncbi Early detection and prognosis of ovarian cancer using serum YKL-40
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3330-9. 2004
    ..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer...
  95. ncbi Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  96. ncbi Epithelial ovarian cancer
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 3:131-41. 2002
    ..Novel approaches to managing minimal residual disease are being tested in hopes of decreasing the number of patients who relapse after achieving complete clinical remission...
  97. ncbi Economic outcomes of breast cancer survivorship: CALGB study 79804
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 91:153-61. 2005
    ..Over 80% of women diagnosed with breast cancer will be survivors. We sought to determine the economic consequences of surviving breast cancer...
  98. ncbi Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
    Don S Dizon
    Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Gynecol Oncol 84:378-82. 2002
    ..Routine retreatment of carboplatin-allergic patients with cisplatin in the relapsed setting cannot be recommended without careful consideration of potential risks and benefits...
  99. ncbi Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up
    Noah D Kauff
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:314-20. 2005
    ..Limited information is available regarding the impact of this approach on either quality of life (QOL) or need for invasive follow-up in this group of women...
  100. ncbi Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival
    Nadeem R Abu-Rustum
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1096, New York, NY 10021, USA
    Gynecol Oncol 99:320-6. 2005
    ....
  101. ncbi Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY 10021, USA
    J Clin Oncol 25:2755-63. 2007
    ..To determine if the addition of docetaxel to gemcitabine improved clinical outcome of patients with metastatic soft tissue sarcomas, we compared a fixed dose rate infusion of gemcitabine versus a lower dose of gemcitabine with docetaxel...